Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas

Table 5 Performance of each serum tumor maker in predicting advanced mucinous cystic neoplasms

	Overall	Benign	Advanced	P value1
CA19-9 (n = 31)
Median, IQR (U/mL)	14.7 (7.3-108.1)	7.73 (5.63-24.2)	157 (15.7-1100)	0.001
≥ 37/< 37 U/mL	10/26	2/21	8/5	0.003
CEA (n = 31)
Median, IQR (ng/mL)	1.5 (1.05-2.58)	1.5 (1.0-1.87)	2.56 (1.31-5.57)	0.004
≥ 5/< 5 ng/mL	3/33	0/23	3/10	0.04
CA125 (n = 26)
Median, IQR (U/mL)	14.5 (10.0-25.7)	14.4 (9.2-20.1)	68.6 (11.9-125)	< 0.0001
≥ 35 /< 35 U/mL	5/21	0/19	5/2	< 0.0001
CA724 (n = 20)
Median, IQR (U/mL)	1.5 (0.96-2.7)	1.52 (0.99-2.24)	1.53 (0.8-6.8)	0.538
≥ 9.8/< 9.8 U /mL	1/19	1/14	0/5	1.00
CA242 (n = 3)
Median, IQR (U/mL)	2.39 (0.1)	1.25 (0.1)	35.35	Not applicable
≥ 20/< 20 U/mL	1/2	0/2	1/0	0.333

¹P values were based on student’s t test comparing mean values of each serum tumor maker. CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; IQR: Interquartile range.